Development of PEGylated adenovirus vector with targeting ligand

被引:66
作者
Eto, Yusuke [1 ]
Yoshioka, Yasuo [1 ,2 ]
Mukai, Yohei [1 ]
Okada, Naoki [1 ]
Nakagawa, Shinsaku [1 ,2 ]
机构
[1] Osaka Univ, Grad Sch Pharmaceut Sci, Dept Biotechnol & Therapeut, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Ctr Adv Med Engn & Informat, Suita, Osaka 5650871, Japan
关键词
adenovirus vector; PEGylation; targeting;
D O I
10.1016/j.ijpharm.2007.08.025
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
For effective gene therapy, a vector system that transduces the therapeutic gene into target cells efficiently and safely is essential. Adenovirus (Ad) vectors frequently are used for gene therapy research, especially cancer gene therapy, because of their high transduction efficiency. However, broad clinical utility of Ad vectors have not yet been achieved owing to problems related to several properties inherent to Ads. Systemic administration of Ad vectors leads to acute virus accumulation and undesirable transgene expression in the liver, with subsequent inefficient systemic cancer-targeted therapy and pronounced hepatotoxicity. Furthermore, most people have Ad-neutralizing antibodies, which hamper gene expression efficiency. Chemical conjugation of Ad surface with polyethylene glycol (PEG) (PEGylation) is one of the promising strategies to overcome these problems. Furthermore, PEGylation of Ad vectors with targeting ligands on the tip of PEG, which alter the transfection range of Ad vectors will improve the safety and efficiency of Ad gene-delivery vectors. In this review, we describe the molecular biology of Ads and outline this PEGylation approach including our data. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:3 / 8
页数:6
相关论文
共 39 条
  • [1] Blood clearance rates of adenovirus type 5 in mice
    Alemany, R
    Suzuki, K
    Curiel, DT
    [J]. JOURNAL OF GENERAL VIROLOGY, 2000, 81 : 2605 - 2609
  • [2] CAR-binding ablation does not change biodistribution and toxicity of adenoviral vectors
    Alemany, R
    Curiel, DT
    [J]. GENE THERAPY, 2001, 8 (17) : 1347 - 1353
  • [3] Anderson W.F., 1990, Hum Gene Ther, V1, P331
  • [4] T-LYMPHOCYTE-DIRECTED GENE-THERAPY FOR ADA(-) SCID - INITIAL TRIAL RESULTS AFTER 4 YEARS
    BLAESE, RM
    CULVER, KW
    MILLER, AD
    CARTER, CS
    FLEISHER, T
    CLERICI, M
    SHEARER, G
    CHANG, L
    CHIANG, YW
    TOLSTOSHEV, P
    GREENBLATT, JJ
    ROSENBERG, SA
    KLEIN, H
    BERGER, M
    MULLEN, CA
    RAMSEY, WJ
    MUUL, L
    MORGAN, RA
    ANDERSON, WF
    [J]. SCIENCE, 1995, 270 (5235) : 475 - 480
  • [5] Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
    Cavazzana-Calvo, M
    Hacein-Bey, S
    Basile, CD
    Gross, F
    Yvon, E
    Nusbaum, P
    Selz, F
    Hue, C
    Certain, S
    Casanova, JL
    Bousso, P
    Le Deist, F
    Fischer, A
    [J]. SCIENCE, 2000, 288 (5466) : 669 - 672
  • [6] PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver
    Croyle, MA
    Chirmule, N
    Zhang, Y
    Wilson, JM
    [J]. HUMAN GENE THERAPY, 2002, 13 (15) : 1887 - 1900
  • [7] Stealth adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung
    Croyle, MA
    Chirmule, N
    Zhang, Y
    Wilson, JM
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (10) : 4792 - 4801
  • [8] Development of a rapid method for the PEGylation of adenoviruses with enhanced transduction and improved stability under harsh storage conditions
    Croyle, MA
    Yu, QC
    Wilson, JM
    [J]. HUMAN GENE THERAPY, 2000, 11 (12) : 1713 - 1722
  • [9] DELGADO C, 1992, CRIT REV THER DRUG, V9, P249
  • [10] PEGylated adenovirus vectors containing RGD peptides on the tip of PEG show high transduction efficiency and antibody evasion ability
    Eto, Y
    Gao, JQ
    Sekiguchi, F
    Kurachi, S
    Katayama, K
    Maeda, M
    Kawasaki, K
    Mizuguchi, H
    Hayakawa, T
    Tsutsumi, Y
    Mayumi, T
    Nakagawa, S
    [J]. JOURNAL OF GENE MEDICINE, 2005, 7 (05) : 604 - 612